Drug safety evaluation profile of stavudine plus lamivudine for HIV-1/AIDS infection

Bibliography

• Domingo P, Vidal F. Combination antiretroviral therapy. Expert Opin Pharmacother 2011; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Hogg RS, O’Shaughnessy MV, Gataric N, Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997;349:1294
   PubMed Web of Science ®Google Scholar
• Crum NF, Riffenburgh RH, Wegner S, Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 2006;41:194-200
   PubMed Web of Science ®Google Scholar
• Palella FJ, Baker RK, Moorman AC, Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006;43:27-34
   PubMed Web of Science ®Google Scholar
• Wang C, Vlahov D, Galai N, Mortality in HIV-Seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis 2004;190(6):1046-54
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 10, 2011; 1–166. Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf [Last accessed 4 March 2011]
   Google Scholar
• Thompson MA, Aberg JA, Cahn P, Antiretroviral treatment of adult HIV infection. 2010 recommendations of the International AIDS Society–USA Panel. JAMA 2010;304(3):321-33
   PubMed Web of Science ®Google Scholar
• European AIDS Clinical Society. Clinical management and treatment of HIV infected adults in Europe. November 22, 2009; 1-25. Available from: http://www.erupeanaidsclinicalsociety.org [Last accessed 4 March 2011]
   Google Scholar
• Documento de consenso de Gesida/Plan Nacional sobre el Sida sobre el tratamiento antiretroviral del adulto. Panel de expertos de Gesida y Plan Nacional sobre el Sida. January 2011; 1-239
   Google Scholar
• Yeni PG, Hammer SM, Carpenter CCJ, Antiretroviral Treatment for Adult HIV Infection in 2002: updated Recommendations of the International AIDS Society-USA Panel. JAMA 2002;288(2):222-35
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Addendum to 2006 HIV Treatment Guidelines. Available from: http://www.who.int/hiv/art/ARTadultsaddendum.pdf [Last accessed 22 July 2011]
   Google Scholar
• Hill A, Ruxrungtham K, Hanvanich M, Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother 2007;8:1-10
   PubMedGoogle Scholar
• World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. November 30, 2009;1-28. Available from: http://www.who.int/hiv/pub/arv/advice/en/index.html [Last accessed 4 March 2011]
   Google Scholar
• Available from: http://www.ema.europa.eu/findmedicine/humanmedicines/europeanpublicassessmentreports [Last accessed 4 March 2011]
   Google Scholar
• Weller IV, Williams IG. ABC of AIDS. Antiretroviral drugs. BMJ 2001;322(7299):1410-12
   PubMed Web of Science ®Google Scholar
• Dieterich DT. Long-term complications of nucleoside reverse transcriptase inhibitor therapy. AIDS Read 2003;13:176-87
   PubMedGoogle Scholar
• Brinkman K, Smeitink JA, Romijn JA, Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999;354:1112-15
   PubMed Web of Science ®Google Scholar
• Gallant JE, Staszewski S, Pozniak AL, Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients. A 3-Year Randomized Trial. JAMA 2004;292(2):191-201
   PubMed Web of Science ®Google Scholar
• Cassetti I, Madruga JV, Suleiman JM, The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials 2007;8:164-72
   PubMed Web of Science ®Google Scholar
• Van Leth F, Hassink E, Phanuphak P, Results of the 2NN Study: A Randomized Comparative Trial of First-line Antiretroviral Therapy with Regimens Containing Either Nevirapine Alone, Efavirenz Alone or Both Drugs Combined, Together with Stavudine and Lamivudine [abstract 176]. 10th Conference on Retroviruses and Opportunistic Infections; 10 – 14 Feb 2003; Boston
   Google Scholar
• Van Leth F, Hall DB, Lange JMA, Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine. HIV Med 2006;7:347-50
   PubMed Web of Science ®Google Scholar
• Haubrich RH, Riddler SA, DiRienzo AG, Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009;23(9):1109-18
   PubMed Web of Science ®Google Scholar
• Huang J, Hughes M, Riddler S, Effects of randomized regimen and nucleoside reverse transcriptase inhibitor (NRTI) selection on 96 week bone mineral density (BMD): results from ACTG 5142 [abstract WEAB0304]. Program and abstracts of the 18th International AIDS Conference; 18 – 23 July 2010; Vienna, Austria
   Google Scholar
• Ratsela A, Polis M, Dhlomo S, A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count < 200 cells/muL in South Africa. J Infect Dis 2010;202(10):1529-37
   PubMed Web of Science ®Google Scholar
• Joly V, Flandre P, Meiffredy V, Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (Novavir Trial). Antimicrob Agents Chemother 2002;46(6):1906-13
   PubMed Web of Science ®Google Scholar
• Joly V, Flandre P, Meiffredy V, Increased risk of lipoatrophy under stavudine In HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2002;16(18):2447-54
   PubMed Web of Science ®Google Scholar
• Squires KE, Gulick R, Tebas P, A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). AIDS 2000;14(11):1591-600
   PubMed Web of Science ®Google Scholar
• Carr A, Chuah J, Hudson J, A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study. AIDS 2000;14(9):1171-18
   PubMed Web of Science ®Google Scholar
• French M, Amin J, Roth N, Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 infection: the OzCombo2 Study. HIV Clin Trials 2002;3(3):177-85
   PubMedGoogle Scholar
• Kumar PN, Rodriguez-French A, Thompson MA, A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. HIV Medicine 2006;7:85-98
   PubMed Web of Science ®Google Scholar
• Podzamczer D, Ferrer E, Sanchez P, ABCDE (Abacavir vs. d4T (stavudine) plus efavirenz) Study Team. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. Acquir Immune Defic Syndr 2007;44:139-47
   PubMed Web of Science ®Google Scholar
• Sacktor N, Nakasujja N, Skolasky RL, Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda. Neurology 2009;72(2):165-70
   PubMed Web of Science ®Google Scholar
• Zhou J, Paton NI, Ditangco R, Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the treat Asia HIV observational database. HIV Med 2007;8:8-16
   PubMed Web of Science ®Google Scholar
• Mouhari-Toure A, Saka B, Kombat K, Clinical safety of a generic fixed-dose combination of stavudine/lamivudine/nevirapine (Triomune). Study of 297 cases in Togo. Bull Soc Pathol Exot 2008;101:404-6
   PubMedGoogle Scholar
• Manosuthi W, Chimsuntorn S, Likanonsakul S, Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 < 50 versus CD4 > or = 50 cells/mm3. AIDS Res Ther 2007;13:4-6
   Google Scholar
• Getahun A, Tansuphasawadikul S, Desakorn V, Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (gpo-vir) in advanced HIV infection. J Med Assoc Thai 2006;89(9):1472-8
   PubMedGoogle Scholar
• Anekthananon T, Tatanasuwan W, Techasathit W, Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study. J Med Assoc Thai 2004;87(7):760-7
   PubMedGoogle Scholar
• Srirangaraj S, Venkatesha D. Adverse effects after HAART Initiation in resource-limited settings: a prospective study from Mysore, India. J Infect Dev Ctries 2010;4(11):750-3
   PubMedGoogle Scholar
• Laurent C, Kovanfack CH, Koulla-chiro S, Effectiveness and safety of a generic fixed dose combination of nevirapine, stavudine and lamivudine in HIV-1-infected adults in Cameroon: open label multicentre trial. Lancet 2004;364:29-34
   PubMed Web of Science ®Google Scholar
• Ribera E, Paradineiro JC, Domingo P, A randomized study comparing the efficacy and tolerability of low-dose versus standard-dose stavudine in antiretroviral-naive patients (ETOX Study) [abstract TuPe2.4c10]. 3rd International Conference on EIDS Pathogenesis; July 2005; Rio de Janeiro, Brazil
   Google Scholar
• Sanchez-Conde M, Soriano V, Gonzalez-Lahoz J. Dose reduction in stavudine from 40 to 30 mg bid provides similar virological and immunological benefit [abstract TuPeB4459]. 15th International Conference on AIDS; 11 – 16 July 2004; Bangkok, Thailand
   Google Scholar